[1]
M. Szkultecka-Dębek, M. Drozd, N. Wiśniewska, and K. Drozd, “Adverse events (AE) costs assessed in Poland based on existing Drug Programs – methodology of the project”, Curr. Issues Pharm. Med. Sci., vol. 26, no. 4, pp. 422–424, Dec. 2013, doi: 10.12923/j.2084-980X/26.4/a.16.